



11th August 2016

## BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
<b>Indices</b>			
Dow Jones	18495.66	-0.20%	+6.14%
S&P 500	2175.49	-0.29%	+6.44%
Nasdaq	5204.58	-0.40%	+3.94%
Nikkei	16735.12	-0.18%	-12.08%
Stoxx 600	343.978	-0.20%	-5.97%
CAC 40	4452.01	-0.36%	-3.99%
<b>Oil /Gold</b>			
Crude WTI	41.71	-2.48%	+12.12%
Gold (once)	1344.7	+0.34%	+26.57%
<b>Currencies/Rates</b>			
EUR/USD	1.1163	+0.46%	+2.76%
EUR/CHF	1.0906	-0.08%	+0.29%
German 10 years	-0.168	+19.29%	-126.51%
French 10 years	0.106	-22.21%	-89.17%
Euribor	-	+-%	+-%

### Economic releases :

Date	
11th-Aug	US - Initial Jobless Claims Aug. (265K E) US - Continuing Claims Jul. (2130K E) CAD - New Housing Price Index Jun.

### Upcoming BG events :

Date	
1st-Sept	L'OREAL (BG Paris roadshow with CFO)
8th-Sept	ACCOR (BG Roadshow with CFO)
13th-Sept	Thematic Breakfast with ARCEP
14th-Sept	SAINT GOBAIN (BG Luxembourg roadshow)
22nd-Sept	Thematic Lunch with HC specialist
30th-Sept	Thematic Breakfast with Vimpelcom

### Recent reports :

Date	
26th-Jul	NICOX Don't turn a blind eye to opportunities
21st-Jul	SEMICONDUCTORS : Looking for lost growth
13th-Jul	Oncology is an increased focus
12th-Jul	DANONE No redemption
1st-Jul	UBISOFT Same player shoot again?
29th-Jun	ORANGE : Lights are turning green.

List of our Reco & Fair Value : Please click here to download



### RWE

**NEUTRAL, Fair Value EUR9.5 (-37%)**

*A H1-16 EBITDA down 5% YoY and 5.4% below market expectations*

RWE posted this morning poor H1-16 metrics as expected, despite solid growth coming from regulated activities and despite recovery on its UK supply activities. On almost all metrics, consensus was too high by around 5-6% putting potentially current market expectations for 2016 at risk. Despite that, 2016 targets have been reiterated for the group, as well as for Innogy. We maintain our Neutral rating with FV unchanged at EUR9.5 and still see as unjustified the recent share price surge.

### In brief...

**AEGON, Disappointing Q2 operating numbers but ongoing efforts on capital mgt. and dividend**

**GENMAB, An ex-oncology deal with Gilead further validating the bispecific platform**

**ZURICH INSURANCE GROUP, Strong Q2, driven by P&C. Waiting for 17th Nov. Investors' Day**

Utilities

**RWE**

Price EUR15.05

**A H1-16 EBITDA down 5% YoY and 5.4% below market expectations**

**Fair Value EUR9.5 (-37%)**

**NEUTRAL**

Bloomberg	RWE GR
Reuters	RWEG.DE
12-month High / Low (EUR)	18.6 / 9.2
Market Cap (EUR)	9,092
Ev (BG Estimates) (EUR)	46,626
Avg. 6m daily volume (000)	4,749
3y EPS CAGR	

**RWE posted this morning poor H1-16 metrics as expected, despite solid growth coming from regulated activities and despite recovery on its UK supply activities. On almost all metrics, consensus was too high by around 5-6% putting potentially current market expectations for 2016 at risk. Despite that, 2016 targets have been reiterated for the group, as well as for Innogy. We maintain our Neutral rating with FV unchanged at EUR9.5 and still see as unjustified the recent share price surge.**

**ANALYSIS**

- Main H1-16 metrics:** EBITDA came out at **EUR3bn** down 5% compared with last year and **missed by 5.4% consensus expectations** while adjusted operating income is down 7% and is 5.8% below market expectations. As expected most of the earnings drop is coming from **1/lower earning** from trading activities, **2/from increased costs** to operate and maintain the distribution grid at group's infrastructure business, and **3/from lower revenues** at group's renewables business due to lower wholesale prices and to negative base effect with last year (book gain from disposals). The group benefited also from positive earnings growth generated by its power and gas supply division thanks notably to the recovery of the UK business. All in all group' adjusted net income (restated from provisions and negative non operating elements) is up 10% to **EUR598m** while consensus was expecting EUR634m. Net debt is up compared with end 2015, by **EUR2.8bn** to **EUR28.3bn** due notably to lower operating cash flow generation and to a EUR2bn surge in pension, nuclear and mining provisions (change in interest/discount rates).
- What to retain from this publication?** **1/H1-16 metrics** are **5-6%** below market expectations, all almost all metrics, **2/Despite** this poor year's start **the group confirmed its guidance for 2016** and then still targets to generate an EBITDA between **EUR5.2bn** and **EUR5.5bn** (consensus is currently at EUR5.4bn) and an operating result of **EUR2.8bn-3.1bn** (consensus is at EUR3bn). The guidance implies a lower H2 compared with H1. **3/Targets** for new entity Innogy was also reiterated with the group targeting to generate an EBITDA of around **EUR4.1-4.4bn** fueled mainly by the solid performance coming from grid business. Group's management indicated the preparation for the IPO is well on track. **4/Despite** all discussions, a consensus has not been found yet between German government and RWE and other utilities about the way to finance the nuclear exit, putting in our view group's current EV at risk.
- Conclusion:** As for E.ON, group's performance for the first semester is poor, yet is not poor enough to put group's guidance at risk. Yet given the 5-6% miss compared with market expectations we expect a negative earnings adjustment on 2016 market expectations. As of today the risk on nuclear dismantling costs remain important, and could still alter significantly group's balance sheet despite all investors's recent attractiveness for Innogy. At this stage we confirm the Hold rating with FV unchanged at EUR9.5 per share. The recent share price surge is in our view not justified.

	1 M	3 M	6 M	31/12/15
Absolute perf.	1.1%	26.9%	33.6%	28.5%
Utilities	-0.1%	0.1%	5.9%	-3.8%
DJ Stoxx 600	5.1%	2.3%	9.1%	-6.0%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	48,599	48,259	48,337	48,416
% change		-0.7%	0.2%	0.2%
EBITDA	7,017	5,461	5,543	5,234
EBIT	3,837	3,002	3,095	2,820
% change		-21.8%	3.1%	-8.9%
Net income	-170.0	483.0	533.8	361.4
% change		NS	10.5%	-32.3%

	2015	2016e	2017e	2018e
Operating margin	7.9	6.2	6.4	5.8
Net margin	-0.3	1.0	1.1	0.7
ROE	-19.0	8.3	9.3	7.7
ROCE	6.4	5.0	5.2	4.9
Gearing	186.2	200.8	206.8	217.3

(EUR)	2015	2016e	2017e	2018e
EPS	-0.28	0.79	0.87	0.59
% change		NS	10.5%	-32.3%
P/E	NS	19.1x	17.3x	25.6x
FCF yield (%)	NM	NM	9.7%	10.5%
Dividends (EUR)	0.00	0.00	0.00	0.00
Div yield (%)	NM	NM	NM	NM
EV/Sales	0.9x	1.0x	1.0x	1.0x
EV/EBITDA	6.5x	8.5x	8.4x	8.9x
EV/EBIT	11.9x	15.5x	15.1x	16.5x



**VALUATION**

- At current share price, RWE is trading at 8.5x its 2016e EV/EBITDA multiple
- Neutral, FV @ EUR9.5

**NEXT CATALYSTS**

- 14<sup>th</sup> November 2016: Q3-16 results:

[Click here to download](#)



**Analyst :**  
 Xavier Caroen  
 33(0) 1.56.68.75.18  
 xcaroen@bryangarnier.com

**Sector Team :**  
 Pierre-Antoine Chazal

## Insurance

**Aegon**

Price EUR3.85

**Disappointing Q2 operating numbers but ongoing efforts on capital mgt. and dividend****Fair Value EUR6 (+56%)****NEUTRAL**

Bloomberg	AGN NA
Reuters	AEGN.AS
12-month High / Low (EUR)	6.9 / 3.0
Market Cap (EUR)	8,303
Avg. 6m daily volume (000)	10,063

**ANALYSIS**

- Q2 2016 net income is –EUR385m, pretty much in line with consensus (-EUR355m), mainly driven by the expected book loss on divestment of UK annuity book and fair value items.
- Q2 operating profit is EUR435m, down 14% yoy, below consensus (EUR481m), with higher earnings from Europe (up 15%, in line with consensus) more than offset by the Americas (down 24% on adverse claims experience, low interest rates and lower variable annuity earnings).
- The Americas will experience a new set of restructuring actions to deal with this recurring disappointing operating performance, including cost discipline, portfolio review and disposal of non-core assets.
- Q2 new life sales down 11% considering the current rate environment is not favourable to grow the business. Q2 NBV is EUR100m, down 46% yoy, mainly driven by lower interest rates on both sales and margins.
- Solvency II margin at end-June is 158% (consensus 154%) vs. 155% at end-March and 160% at end-2015, as strong management actions (including the UK annuity book divestment) offset adverse market impacts.
- The interim dividend is up 8% to EUR0.13 (i.e. 6.8% annualised yield at current share price). The dilutive effect of stock dividend will be neutralize.

**VALUATION**

- Based on our current estimates, our SOTP valuation is EUR6.

**NEXT CATALYSTS**

- Q3 2016 numbers on November 10<sup>th</sup>.

Olivier Pauchaut, opauchaut@bryangarnier.com

	1 M	3 M	6 M	31/12/15
Absolute perf.	16.6%	-21.1%	-12.3%	-26.4%
Insurance	10.4%	-3.0%	0.9%	-18.0%
DJ Stoxx 600	5.1%	2.3%	9.1%	-6.0%

	2015	2016e	2017e	2018e
P/E	5.3x	5.3x	5.0x	
Div yield (%)	6.5%	7.1%	7.9%	

## Healthcare

**Genmab**

Price DKK1,167

**An ex-oncology deal with Gilead further validating the bispecific platform****Fair Value DKK1600 (+37%)****BUY**

Bloomberg	GEN.DC
Reuters	GEN.CO
12-month High / Low (DKK)	1,266 / 548.0
Market Cap (DKKm)	69,826
Avg. 6m daily volume (000)	466.2

	1 M	3 M	6 M	31/12/15
Absolute perf.	-2.9%	16.9%	73.1%	27.2%
Healthcare	-0.7%	6.0%	10.9%	-5.5%
DJ Stoxx 600	5.1%	2.3%	9.1%	-6.0%

	2015	2016e	2017e	2018e
P/E	NS	NS	NS	56.5x
Div yield (%)	NM	NM	NM	NM

**ANALYSIS**

- **Genmab has inked a collaboration agreement with Gilead to create a DuoBody (bispecific antibody) to treat HIV.** Under the terms of the agreement, 1/ GEN will receive an upfront payment of USD5m, as well as up to USD277m milestones payments and single-digit royalties; 2/ Gilead has an option to obtain a second exclusive option (and we believe this might involve another therapeutic field, e.g. NASH, inflammation).
- **The potential targeted antigens were not disclosed**, but we note that gp120, gp41 and CD4 are targets for which the industry has paid a particular attention recently.
- **We see this as another strong validation of the attractiveness of GEN's bispecific platform...** Knowing that several other collaborations have been concluded over the past few years, in oncology and potentially other fields (e.g. inflammation, and per chance haemophilia).

**VALUATION**

- **BUY rating reiterated with a FV of DKK1,600.**

**NEXT CATALYSTS**

- November, 10: Capital market day
- Q4: ASH meeting + Daratumumab's label expansion to the second-line of myeloma as part of a combination regimen.

[Click here to download](#)Mickael Chane Du, [mchanedu@bryangarnier.com](mailto:mchanedu@bryangarnier.com)

## Insurance

**Zurich Insurance Group**

Price CHF242.90

**Strong Q2, driven by P&C. Waiting for 17<sup>th</sup> Nov. Investors' Day****Fair Value CHF270 (+11%)****NEUTRAL**

Bloomberg	ZURN.VX
Reuters	ZURN.VX
12-month High / Low (CHF)	291.6 / 196.0
Market Cap (CHF)	36,564
Avg. 6m daily volume (000)	685.9

	1 M	3 M	6 M	31/12/15
Absolute perf.	6.1%	12.9%	18.2%	-6.0%
Insurance	10.4%	-3.0%	0.9%	-18.0%
DJ Stoxx 600	5.1%	2.3%	9.1%	-6.0%

	2015	2016e	2017e
P/E	18.9x	10.4x	9.8x
Div yield (%)	6.8%	6.8%	6.8%

**ANALYSIS**

- Q2 2016 net income came at USD739m, down 12% yoy, consensus (USD710bn), mainly driven by lower capital gains, restructuring charges and a higher tax rate. Q2 operating profit came at USD1,107m, up 17% yoy, way above consensus (USD0.9bn), driven by P&C.
- Operating profit in P&C was USD663m, up 44% yoy, driven by the underwriting performance and FX gains. The reported combined ratio is 99.0% vs. 100.0% in Q2 2015, but excluding natcats (5.8 points vs. 3.4 points) and run-offs (1.5 point vs. 1.3 point), the underlying combined ratio was 94.7% vs. 97.9% in Q2 2015, which is more in line with competition following a terrible 2015.
- Operating profit in Life was down 2% yoy to USD349m. NBV margin was 24.0% vs. 18.7% in Q2 2015. Inflows were USD2.2bn vs. USD1.6bn in Q2 2015.
- Operating profit at Farmers was up 2% to USD335m, mainly driven by the Management Services (up 6% to USD350m) whereas Reinsurance is slightly negative (108.4% combined ratio).
- Annualised H1 RoI was 3.8% vs. 4.0% in H1 2015.
- Solvency (internal model) at end-June was 107% vs. 108% at end-March and 121% at end-2015, driven by poor financial markets, and still within the 100-120% targeted range. Total cash remittances for the 2014-2016 are still on track to exceed USD10bn, which is good news for the dividend.

**VALUATION**

- Based on our current estimates, our SOTP valuation is CHF270.

**NEXT CATALYSTS**

Olivier Pauchaut, opauchaut@bryangarnier.com



## BG's Wake Up Call

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 55.7%

NEUTRAL ratings 33.6%

SELL ratings 10.7%

## Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	<b>Eric Le Berrigaud</b> <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	<b>Mickael Chane-Du</b>	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	<b>Hugo Solvet</b>	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	<b>Loïc Morvan</b>	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	<b>Nikolaas Faes</b>	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	<b>Antoine Parison</b>	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	<b>Cedric Rossi</b>	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	<b>Virginie Roumage</b>	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	<b>Richard-Maxime Beaudoux</b>	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	<b>Thomas Coudry</b>	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	<b>Gregory Ramirez</b>	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	<b>Dorian Terral</b>	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		<b>Xavier Caroen</b>	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		<b>Pierre-Antoine Chazal</b>	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		<b>Olivier Pauchaut</b> <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		<b>Bruno de La Rochebrochard</b>	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/ Infrastructures Building Materials		<b>Eric Lemarié</b>	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing		<b>Sophie Braincourt</b>	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		<b>Eric Monnier</b>	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

London	Paris	New York	Munich	New Delhi
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA) and Financial Conduct Authority (FCA) the Autorité de Contrôle prudentiel et de résolution (ACPR)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062 <b>Geneva</b> rue de Grenus 7 CP 2113 Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 <b>Regulated by the FINMA</b>



## BRYAN, GARNIER & CO

### Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

### Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

#### Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

#### Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

#### Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

#### Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....